January 15th, 2019
At PEP Talk on Jan 15th 2019 at Chi-PEP TALK 2019 in San Diego, Celltheon presents about the challenges in BioTherapeutic production and Celltheon's solution using the "CELLTHEON SMART™ PLATFORM" along with Pall Biotech scale up solution.
12:40 Luncheon Presentation I A SMART Platform for Scalable Biotherapeutic Development: cDNA to 200L Single-use Stirred-tank Bioreactor – a Case Study and Workflow
At PEP Talk on Jan 15th 2019 at Chi-PEP TALK 2019 in San Diego, Celltheon presents about the challenges in BioTherapeutic production and Celltheon's solution using the "CELLTHEON SMART™ PLATFORM" along with Pall Biotech scale up solution.
12:40 Luncheon Presentation I A SMART Platform for Scalable Biotherapeutic Development: cDNA to 200L Single-use Stirred-tank Bioreactor – a Case Study and Workflow
April 10, 2017
Biosimilars Article: Don't Buy New Cell Line or RCB !! Save Millions by Doing This Instead...
Biosimilars Article: Don't Buy New Cell Line or RCB !! Save Millions by Doing This Instead...
March 14-17, 2016
BioProcess International, West Coat in Oakland California
Celltheon CEO to give Keynote address to conference attendees.
BioProcess International, West Coat in Oakland California
Celltheon CEO to give Keynote address to conference attendees.
January 5th, 2016
Celltheon expands and moves to new location in Union City
Celltheon expands and moves to new location in Union City
October, 2015
CEO Teaches Mammalian Cell Culture Intensive at KGI
CEO Teaches Mammalian Cell Culture Intensive at KGI
May 18-20th, 2015
Cell line development and Engineering conference
Celltheon presents data on Celltheon's SMART Expression Platform a novel technology for generating manufacturing cell lines.
Cell line development and Engineering conference
Celltheon presents data on Celltheon's SMART Expression Platform a novel technology for generating manufacturing cell lines.
January 21, 2015
CHI PepTalk Presentation & Buzz Session
Celltheon to present at CHI PEP in San Diego. The talk is on Celltheon's SMART expression system. Meet up with Celltheon employees at the CHO sub session during the podium presentation and the followup buzz sessions.
CHI PepTalk Presentation & Buzz Session
Celltheon to present at CHI PEP in San Diego. The talk is on Celltheon's SMART expression system. Meet up with Celltheon employees at the CHO sub session during the podium presentation and the followup buzz sessions.
October 21-25, 2014
Amita Goel to teach Mammalian Cell Culture Intensive at KGI
Advances in mammalian cell technology over the past three decades, combined with major developments in therapeutic proteins and antibodies, have made the recombinant Chinese Hamster Ovary (CHO) cells the expression of choice in biotech manufacturing. In traditional mechanically stirred bioreactors, production levels have increased 10,000-fold during the same period and product protein titers are now routinely measured in grams per liter. These achievements are leading to significant cell culture bioprocess sophistication, and, along with emerging single use technologies, are making the future flexible bioprocess manufacturing a distinct possibility. This five day intensive laboratory based course is designed for professional scientists and engineers who wish to enhance their basic knowledge and training in upstream functional areas including cell culture and primary recovery. The primary goal of the course is to update the participants' background in mammalian cell biotechnology, from cell line design, development and optimization to bioreactor design, scale up and operation. The course will be delivered by a team of senior industry and academic experts at the Amgen Bioprocessing Center (ABC) at Keck Graduate Institute in Claremont, California, from July 21-25, 2014.
Amita Goel to teach Mammalian Cell Culture Intensive at KGI
Advances in mammalian cell technology over the past three decades, combined with major developments in therapeutic proteins and antibodies, have made the recombinant Chinese Hamster Ovary (CHO) cells the expression of choice in biotech manufacturing. In traditional mechanically stirred bioreactors, production levels have increased 10,000-fold during the same period and product protein titers are now routinely measured in grams per liter. These achievements are leading to significant cell culture bioprocess sophistication, and, along with emerging single use technologies, are making the future flexible bioprocess manufacturing a distinct possibility. This five day intensive laboratory based course is designed for professional scientists and engineers who wish to enhance their basic knowledge and training in upstream functional areas including cell culture and primary recovery. The primary goal of the course is to update the participants' background in mammalian cell biotechnology, from cell line design, development and optimization to bioreactor design, scale up and operation. The course will be delivered by a team of senior industry and academic experts at the Amgen Bioprocessing Center (ABC) at Keck Graduate Institute in Claremont, California, from July 21-25, 2014.
June 23-26, 2014
BIO International Convention in San Diego
We look forward to seeing you in San Diego.
BIO International Convention in San Diego
We look forward to seeing you in San Diego.
June 10-11, 2014
CELLTHEON Presents at The Annual Bio Manufacturing & Process Innovation Leaders Summit in Boston
CEO presents on development of innovative and cost effective solutions in bioprocessing.
CELLTHEON Presents at The Annual Bio Manufacturing & Process Innovation Leaders Summit in Boston
CEO presents on development of innovative and cost effective solutions in bioprocessing.
April 15, 2014
CELLTHEON Presents at Bio2Device
Biotherapeutic drug development continues to be a rapidly growing field and a large number of these drugs, like monoclonal antibodies have been approved for treatment of patients. It is estimated that hundreds of new monoclonal antibodies could enter preclinical and clinical development each year. There is still considerable unmet medical need in the three main areas of study - cancer, immunological and infectious diseases, and these emerging agents could provide valuable new treatment options. Also with the growth in Biosimilar, the global competition for biologics manufacturing has put immense pressure to shorten time to market. Growth and state of the art in the biotechnology industry promises to shrink developmental workflows by substituting time-intensive steps with rapid ones, thus shortening product and process development timelines.
CELLTHEON Presents at Bio2Device
Biotherapeutic drug development continues to be a rapidly growing field and a large number of these drugs, like monoclonal antibodies have been approved for treatment of patients. It is estimated that hundreds of new monoclonal antibodies could enter preclinical and clinical development each year. There is still considerable unmet medical need in the three main areas of study - cancer, immunological and infectious diseases, and these emerging agents could provide valuable new treatment options. Also with the growth in Biosimilar, the global competition for biologics manufacturing has put immense pressure to shorten time to market. Growth and state of the art in the biotechnology industry promises to shrink developmental workflows by substituting time-intensive steps with rapid ones, thus shortening product and process development timelines.
March 5, 2014
CELLTHEON Hosted by EPPIC
Biotherapeutic drug development continues to be a rapidly growing field. A large number of these drugs, like monoclonal antibodies, have been approved for treatment of patients with cancer, inflammatory disease and multiple rare diseases due to their highly targeted and specific nature. Researchers are in constant need of novel and unique technologies that allow them to develop biotherapeutics faster in order to accelerate their drugs into the clinic. However regulatory demands continue to be high and robust and reproducible processes are required to meet them. Join us for a panel discussion on current technologies related to various mammalian expression systems, process optimization methods, downstream purification technologies, large scale manufacturing and various analytical tools to support the development of these drugs.
CELLTHEON Hosted by EPPIC
Biotherapeutic drug development continues to be a rapidly growing field. A large number of these drugs, like monoclonal antibodies, have been approved for treatment of patients with cancer, inflammatory disease and multiple rare diseases due to their highly targeted and specific nature. Researchers are in constant need of novel and unique technologies that allow them to develop biotherapeutics faster in order to accelerate their drugs into the clinic. However regulatory demands continue to be high and robust and reproducible processes are required to meet them. Join us for a panel discussion on current technologies related to various mammalian expression systems, process optimization methods, downstream purification technologies, large scale manufacturing and various analytical tools to support the development of these drugs.
Janurary 23, 2014
CELLTHEON CEO Presents at ISPE CEO Night
The ISPE San Francisco chapter hosts their yearly CEO Night featuring three industry leaders, including Amita Goel from CELLTHEON, Stefan Ryser form Trellis Bioscience LLC and Marie- Cecile van de Lavoir from Crystal Bioscience.
CELLTHEON CEO Presents at ISPE CEO Night
The ISPE San Francisco chapter hosts their yearly CEO Night featuring three industry leaders, including Amita Goel from CELLTHEON, Stefan Ryser form Trellis Bioscience LLC and Marie- Cecile van de Lavoir from Crystal Bioscience.
